Biologics World Taiwan 2026: Powering Asia’s Next Biotech Breakthrough As Taiwan accelerates its transformation into a leading biomanufacturing hub under its ‘5+2’ Innovative Industries Plan, Biologics World Taiwan 2026 returns at a pivotal moment for the region’s biotech ecosystem. Building on over a decade of excellence, the conference continues to serve as the country’s premier platform uniting 300+ local and global leaders across biologics manufacturing, R&D, and clinical trials. Taiwan’s government has sharpened its focus on biomedicine, aiming to replicate its semiconductor success story in the biotech sector. This vision is backed by action: in 2025 alone, the government has increased its science and technology budget to NT$146.6 billion (approx. USD 4.6 billion)—a nearly 15% rise—to fund AI-driven medical R&D and national talent development across ministries.

The launch of the Taiwan Bio-Manufacturing Corporation (TBMC)—modeled after TSMC and with 40% government ownership—marks a bold step in anchoring Taiwan as a regional powerhouse for biologics manufacturing. Meanwhile, the experience during the COVID-19 pandemic has only deepened Taiwan’s resolve to secure domestic CDMO capacity for advanced biologics, highlighting its importance to national health security.